CD79A and plasma cell myeloma: In this small cohort, myeloma patients with EBNA-1-specific monoclonal IgA were relatively young at diagnosis (≤63 years), with severe (59–93%) plasma cell infiltration of the bone marrow, characteristics similar to those reported for myeloma patients with EBNA-1-specific monoclonal IgG (12).